Analysts Review ( AMGN ) declares $0.61/share quarterly dividend , in line with previous. Forward yield 1.95% Payable June 6; for shareholders of record May 15; ex-div May 13. Post your comment!
LDL cholesterol. Both firms disclosed in their regulatory filings that the appearance of these side effects could delay or stop the product's development. Pfizer ( PFE ) and Amgen ( AMGN ) are also working on PCSK9 inhibitors. 1 comment!
By David Trainer : Finding the best mutual funds is an increasingly difficult task in a world with so many to choose from. You Cannot Trust Mutual Fund Labels There are at least 222 different Financials mutual funds and at least 618 mutual funds across all sectors. Do investors need that many ...
Amgen Inc. ( AMGN ) declares $0.61/share quarterly dividend , in line with previous. Forward yield 1.93% Payable June 6; for shareholders of record May 15; ex-div May 13. Post your comment!
Amgen ( AMGN ) sets dividend for the second quarter at $.61/share payable on June 6 to shareholders of record May 15. The company also
By David Zanoni: Executive summary: Dyax's patented technology helps leading pharmaceutical companies to develop drugs efficiently at lower costs. Profitability is on the horizon due to new potential revenue sources from its partners. The balance sheet has improved and cash burn is being reduced.
By YCharts : By Jeff Bailey Novartis' ( NVS ) generic unit, Sandoz, has in phase III clinical trials for the U.S. market so-called biosimilar drugs that would compete against original biologics with annual worldwide sales of about $34 billion. That's by far the biggest biosimilar program in the ...
for Medicare and Medicaid Services for its accountable care pilot program. The emergence of competing biosimilar products for Amgen 's Epogen could eventually improve DaVita's profitability. Management has historically followed prudent capital allocation
Biosimilar drugs market
By Chris Katje : Executive summary: · Ligand Pharmaceuticals has 85 fully funded programs in trials · Recently approved Duavive could provide upside to 2014 guidance · Strong gross margins and low share count provides huge profits for shareholders · Unpartnered drug provides catalyst for short term